BUZZ-Stryker rises after Citi resumes coverage with 'buy' rating

Reuters02-27

** Medical device maker Stryker SYK.N rise 1.2% to $395

** Brokerage Citi Research resumes coverage on SYK with "buy" rating; sets PT at $450, 15.3% upside to the stock's last close

** Brokerage says SYK has built a diversified business through multiple buys such as the $4.9 billion Inari medical acquisition, which added Inari's ClotTriever and FlowTriever devices that treat venous thromboembolism (VTE)

** VTE — a disease where blood clots form in veins — is estimated to impact more than 900,000 patients annually in the U.S., brokerage says

** SYK estimates the value of the VTE market at $15 billion globally, including $6 billion in the U.S.

** Citi calls the Inari acquisition "another step in SYK evolution"

** Stock has risen 10.7% in the past 12 months

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2514863412?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 01:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514863412","market":"nz","top_or_hot":-1,"title":"BUZZ-Stryker rises after Citi resumes coverage with 'buy' rating","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Stryker rises after Citi resumes coverage with 'buy' rating </title></head><body>** Medical device maker Stryker SYK.N rise 1.2% to $395** Brokerage Citi Research resumes coverage on SYK with \"buy\" rating; sets PT at $450, 15.3% upside to the stock's last close ** Brokerage says SYK has built a diversified business through multiple buys such as the $4.9 billion Inari medical acquisition, which added Inari's ClotTriever and FlowTriever devices that treat venous thromboembolism (VTE)** VTE — a disease where blood clots form in veins — is estimated to impact more than 900,000 patients annually in the U.S., brokerage says** SYK estimates the value of the VTE market at $15 billion globally, including $6 billion in the U.S.** Citi calls the Inari acquisition \"another step in SYK evolution\"** Stock has risen 10.7% in the past 12 months (Reporting by Padmanabhan Ananthan) ((Padmanabhan.Ananthan@thomsonreuters.com;))</body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Stryker rises after Citi resumes coverage with 'buy' rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Stryker rises after Citi resumes coverage with 'buy' rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nReuters \n2025-02-27 01:33\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Stryker rises after Citi resumes coverage with 'buy' rating </title></head><body>** Medical device maker Stryker SYK.N rise 1.2% to $395** Brokerage Citi Research resumes coverage on SYK with \"buy\" rating; sets PT at $450, 15.3% upside to the stock's last close ** Brokerage says SYK has built a diversified business through multiple buys such as the $4.9 billion Inari medical acquisition, which added Inari's ClotTriever and FlowTriever devices that treat venous thromboembolism (VTE)** VTE — a disease where blood clots form in veins — is estimated to impact more than 900,000 patients annually in the U.S., brokerage says** SYK estimates the value of the VTE market at $15 billion globally, including $6 billion in the U.S.** Citi calls the Inari acquisition \"another step in SYK evolution\"** Stock has risen 10.7% in the past 12 months (Reporting by Padmanabhan Ananthan) ((Padmanabhan.Ananthan@thomsonreuters.com;))</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NARI","symbol_name":"Inari Medical, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nL3N3PH1LQ:1","article_id":"2514863412","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514863412","pubTimestamp":1740591226,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Stryker rises after Citi resumes coverage with 'buy' rating ** Medical device maker Stryker SYK.N rise 1.2% to $395** Brokerage Citi Research resumes coverage on SYK with \"buy\" rating; sets PT at","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"NARI":"Inari Medical, Inc.","SYK":"史赛克"},"translate_title":"花旗恢复“买入”评级后，BUZZ-Stryker股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SYK":0.9,"NARI":0.9},"content_text":"BUZZ-Stryker rises after Citi resumes coverage with 'buy' rating ** Medical device maker Stryker SYK.N rise 1.2% to $395** Brokerage Citi Research resumes coverage on SYK with \"buy\" rating; sets PT at $450, 15.3% upside to the stock's last close ** Brokerage says SYK has built a diversified business through multiple buys such as the $4.9 billion Inari medical acquisition, which added Inari's ClotTriever and FlowTriever devices that treat venous thromboembolism (VTE)** VTE — a disease where blood clots form in veins — is estimated to impact more than 900,000 patients annually in the U.S., brokerage says** SYK estimates the value of the VTE market at $15 billion globally, including $6 billion in the U.S.** Citi calls the Inari acquisition \"another step in SYK evolution\"** Stock has risen 10.7% in the past 12 months (Reporting by Padmanabhan Ananthan) ((Padmanabhan.Ananthan@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2514863412","isCrawlerRequest":true}